Triage Information: 1. Duration of HPSJ Membership 2. Age 3. Fill history of Seasonal Allergy Medications
|
|
- Hugh Chambers
- 5 years ago
- Views:
Transcription
1 MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Seasonal Allergy Medications LAST REVIEW: 5/28/2015 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 5/15, 9/14 LOB AFFECTED: MCL, SJHA (MONTH/YEAR) This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the HPSJ Pharmacy and Therapeutic Advisory Committee. Overview: Many treatment modalities exist for the treatment of seasonal allergies. Each treatment modality has benefits and weaknesses depending on each patient s specific symptomatology. Considerations for PA Approval: HPSJ must have clinical documentation of agents tried. If an intolerance is reported, there must be clinical documentation of the intolerance and pharmacy fill history of that medication. For treatment failure, an adequate trial of the medication at appropriate doses and for an appropriate duration based on the properties of that therapeutic class must be documented. Clinical Justification: Oral allergy medications can provide symptom relief for the broadest range of allergy symptoms (rhinitis, conjunctivitis, itching). 2 nd generation antihistamines are less sedating than first generation antihistamines and all 2 nd generation oral antihistamines have approximately the same level of efficacy and work quickly. All Intranasal corticosteroids also all have approximately the same level of efficacy. These medications may take up to a week or more to control symptoms, but are effective for a broad range of symptoms when used regularly. Please refer to Table 1 for age specific restrictions for each agent. Ocular antihistamines are a good target for patients with conjunctivitis not controlled by an oral antihistamine alone. OTC Visine A, while effective, frequent dosing makes it a less convenient choice than Ketotifen. Non Pharmacological Measures: Allergen avoidance should be recommended to patients. Take steps to reduce poor air quality in the home and make strides to eliminate the offending allergen. During allergy season, time outdoors should be limited. Patients should close windows, wash bedding frequently, and use vacuum cleaners with HEPA filters. Triage Information: 1. Duration of HPSJ Membership 2. Age 3. Fill history of Seasonal Allergy Medications Medication Coverage Policy: Seasonal Allergies Page 1
2 Class Agents for Seasonal Allergies: Table 1: Drugs Reviewed Antihistamines Route of Admin Brand Name Generic Name Medi Cal Limits Benadryl Diphenhydramine Notes Clinical Pearls Cost/Rx* $3.67 Oral May cause 1 st Generation Antihistamine sedation and Periactin Cyproheptadine dizziness. $24.73 Chlor Trimeton Chlorpheniramine $2.98 Tavist Clemastine $16.14 Claritin Loratadine $6.31 Zyrtec Cetirizine 2 nd Generation Antihistamine $5.64 Intraocular Allegra Fexofenadine PA HPSJ third line therapy. $22.07 Visine A Naphazoline/ $8.70 Pheniramine Alaway Ketotifen $11.23 Patanol Olopatadine PA Pataday is nonformulary. Astelin Azelastine ST; PA Azelastine is Step therapy to failure of a 14 day trial of Fluticasone Corticosteroids Nasarel Flunisolide $ $73.97 $48.66 Flonase Fluticasone Propionate $14.22 Mast Cell Stabilizers Intranasal Anticholinergics Leukotriene Receptor Antagonist Intranasal Oral May take 2 Nasacort OTC Triamcinolone Nasacort AQ is $ weeks to non formulary see full Beconase AQ Beclomethasone PA Second Line $ benefit. Rhinocort Aqua Budesonide PA Second Line $ Nasonex Mometasone PA Third Line $ Nasalcrom Cromolyn Sodium $8.60 Atrovent Nasal Spray Ipratropium Bromide NF Singulair Montelukast For use in $21.74 patients with asthma only. QL = Quantity Limit; FL = Fill Limit, NF = Non Formulary *based on HPSJ utilization historical data based on data from 11/2014 4/2015 Medication Coverage Policy: Seasonal Allergies Page 2
3 EVALUATION CRITERIA FOR APPROVAL/EXCEPTION CONSIDERATION Below are the coverage criteria and required information for each agent. These coverage criteria have been reviewed approved by the HPSJ Pharmacy & Therapeutics (P&T) Advisory Committee. For conditions not covered under this Coverage Policy, HPSJ will make the determination based on Medical Necessity as described in HSPJ Medical Review Guidelines (UM06). 1 st Generation Oral Antihistamines Benadryl (Diphenhydramine), Periactin (Cyproheptadine), Chlor Trimeton (Chlorpheniramine), Tavist (Clemastine) 2 st Generation Oral Antihistamines Claritin (Loratadine), Zyrtec (Cetirizine) Allegra (Fexofenadine) o Fexofenadine is reserved for patient with treatment failure of both loratadine and cetirizine. o Drug refill history showing trials of both loratadine and cetirizine and chart notes documenting an intolerance or treatment failure to Loratadine and Cetirizine. Nasal Antihistamines Astelin (Azelastine) o It is step therapy to failing a 14 day trial of formulary intranasal corticosteroids (e.g, fluticasone, flunisolide). o Drug refill history showing trials of a formulary first line intranasal corticosteroid in the previous month and chart notes documenting inadequate control of allergy symptoms with intranasal corticosteroids alone. Other Notes: Consider use of oral antihistamines for a more convenient method of administration, or intranasal corticosteroids for increased efficacy over nasal antihistamines. Ocular Antihistamines Visine A (Naphazoline/Pheniramine), Alaway (Ketotifen). Patanol (Olopatadine) Olopatadine is step therapy to treatment failure of Visine A AND Alaway. Limits: 10 ml per 30 days Clinical documentation of treatment failure of both Visine A and Alaway, including pharmacy fill history. Other Notes: Pataday is non formulary. Mast Cell Stabilizers Nasalcrom (Cromolyn Sodium Nasal Spray) Medication Coverage Policy: Seasonal Allergies Page 3
4 Intranasal Corticosteroids Flonase (Fluticasone), Nasacort 24hr (Triamcinolone), Nasarel (Flunisolide) Rhinocort Aqua (Budesonide), Beconase AQ (Beclomethasone) o Reserved for treatment failure of an adequate trial (7 14 days) of any 2 (two) first line agents (fluticasone, flunisolide, triamcinolone). o Drug refill history showing trials of 2 (two) formulary first line intranasal corticosteroid in the recent past history and chart notes documenting inadequate control of allergy symptoms or intolerance to other intranasal corticosteroids. Nasonex (Mometasone) o Nasonex is reserved for treatment failure of an adequate trial (7 14 days) of any 2 (two) first line agents (fluticasone, flunisolide, Nasacort OTC) AND one second line agent (Beconase AQ, Rhinocort Aqua). Limits: 1 inhaler per 30 days. o Drug refill history showing trials of 2 (two) formulary first line intranasal corticosteroid and 1 (one) second line agent in the recent past history and chart notes documenting inadequate control of allergy symptoms or intolerance to other intranasal corticosteroids. Leukotriene Receptor Blocker Singulair (Montelukast) Limits: 30 tablets per 30 days Other Notes: Restricted for use in patients with asthma. Prepared by: Anil Mallya, PharmD Reviewed by: Jonathan Szkotak, PharmD BCACP REFERENCES 1. Am Fam Physician Jun 15;81(12): HPSJ Formulary Criteria REVIEW & EDIT HISTORY Document Changes Reference Date P&T Chairman Creation of Policy Azelastine doc 5/2007 Allen Shek PharmD BCPS Update to Policy INC Class review 5 07.doc 5/2007 Allen Shek PharmD BCPS Medication Coverage Policy: Seasonal Allergies Page 4
5 Update to Policy NSAH 5 07.doc 5/2007 Allen Shek PharmD BCPS Update to Policy Ophthalmics Feb 08.doc 2/2008 Allen Shek PharmD BCPS Update to Policy Veramyst monograph 6 08.doc 6/2008 Allen Shek PharmD BCPS Update to Policy NSAH doc 9/2008 Allen Shek PharmD BCPS Update to Policy ICS Review doc 9/2008 Allen Shek PharmD BCPS Update to Policy ICS post P&T survey recap.doc 3/2009 Allen Shek PharmD BCPS Update to Policy Azelastine Monograph docx 5/2011 Allen Shek PharmD BCPS Update to Policy Allergy Review docx 9/2014 Jonathan Szkotak PharmD BCACP Note: All changes are approved by the HPSJ P&T Committee before incorporation into the utilization policy Medication Coverage Policy: Seasonal Allergies Page 5
Oral Agents. Formulary Limits. Available Strengths. IR: 4mg ER: 12mg Syrup: 2mg/5ml
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Seasonal Allergy Medications LAST REVIEW: 9/20/2016 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 5/16, 5/15,
More informationOral Agents. Fml Limits. Available Strengths NF NF
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Allergy Medications LAST REVIEW: 9/12/2017 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 9/16, 5/15, 9/14
More informationDisclosure. OTC Review with a Pediatric Twist. Objectives. When to Call a Doctor for Infant. When to Call a Doctor for Child
OTC Review with a Pediatric Twist Disclosure Consultant for Johnson and Johnson Baby Jill A. Morgan, PharmD, BCPS February 2015 Objectives List situations when a child should be referred to physician.
More informationThe Medical Letter. on Drugs and Therapeutics. Drug Some Formulations OTC/Rx Usual Dosage Comments Class Comments Cost 1
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 01/21/2015 Effective date: 02/21/2015 Therapeutic Classes reviewed: Allergen-Specific Immunotherapy
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx
More informationAllergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma
Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going
More information35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationClinical Policy: Antihistamines Reference Number: CP.HNMC.18 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: Reference Number: CP.HNMC.18 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationODACTRA House Dust Mite (Dermatophagoides farina & Dermatophagoides pteronyssinus) allergen extract sublingual tablet
pteronyssinus) allergen extract sublingual tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
More informationAllergic Rhinitis. Patient population: Adults and pediatrics
Guidelines for Clinical Care Ambulatory Allergic Rhinitis Guideline Team Team Leader David A DeGuzman, MD General Medicine Team Members Catherine M Bettcher, MD Family Medicine R Van Harrison, PhD Medical
More informationJagdeep Hundal, MD, Otolaryngology, Head & Neck Surgery 774 Christiana Rd, Suite B4, Newark, DE Phone: Fax:
Allergy Questionnaire Patient Name Date / / 1. What symptoms do you suffer from? Please circle below Eyes: Itchy eyes, tearing, eye redness, eye discharge Ears: Popping sensation, fullness, itching Nose/Sinus:
More informationPREPARATION FOR ALLERGY TESTING *** Please read this information at least one week before your upcoming visit.
PREPARATION FOR ALLERGY TESTING *** Please read this information at least one week before your upcoming visit. In order to obtain valid and useful skin testing results, you will need to stop the use of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Grastek, Oralair, Ragwitek) Reference Number: CP.CPA.111 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of
More informationAvailable Strengths Limits. 200 mg tablets PA. 50 mg, 150 mg, 200 mg, 250 mg tablets. 500 mg/ml solution PA
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Sleeping Disorders P&T DATE: 12/14/2016 THERAPEUTIC CLASS Psychiatric Disorders REVIEW HISTORY: 2/16, 5/15, 2/12 LOB AFFECTED
More information12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB
More informationSinusitis. What are the sinuses? Who develops sinusitis?
Sinusitis Health experts estimate that 37 million Americans are affected by sinusitis every year. Americans spend nearly $6 billion each year on health care costs related to sinusitis. Sinusitis is an
More informationMethacholine Challenge Test
PATIENT & CAREGIVER EDUCATION Methacholine Challenge Test This information will help you prepare for your methacholine challeng e test at Memorial Sloan Kettering (MSK). A methacholine (meth-a-kole-leen)
More informationMEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Smoking Cessation Products LAST REVIEW 5/8/2018 THERAPEUTIC CLASS: Psychiatric Disorders REVIEW HISTORY 5/17, 5/16, 5/15,
More informationComments. Oral Antihistamines. Chronic Drug Treatments. Oral Allergy Medications
Comments: Even though OTC vasoconstrictors and antihistamines are popular, a recent article suggests that these drugs can cause rebound dilation of conjunctival vessels Chronic Drug Treatments Mast Cell
More informationMatt Stumpe, MD Otolaryngologist Mid Kansas Ear, Nose, & Throat
Matt Stumpe, MD Otolaryngologist Mid Kansas Ear, Nose, & Throat Inflammation of the nasal mucosa secondary to an inappropriate hypersensitivity reaction to an allergen IgE mediated immune response with
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: House dust mite allergen extract (Odactra) Reference Number: CP.PMN.111 Effective Date: 08.01.17 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important
More informationVolume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010
Volume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010 PACEF Recommendations Recommended medicines remain the same as in recent years: Non-sedating antihistamines: generic
More informationINDEX. Note: Page numbers in italics indicate figures. Page numbers followed by t refer to tables. Numbers preceded by CP indicate Color Plates.
INDEX Note: Page numbers in italics indicate figures. Page numbers followed by t refer to tables. Numbers preceded by CP indicate Color Plates. ABRS. See Bacterial rhinosinusitis, acute. Acaricides, 40t,
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 211 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationLungs SLO Practice (online) Page 1 of 5
Lungs SLO Practice (online) Page 1 of 5 1. A 15 year- old teen has asthma. A nebulizer treatment has been ordered. The type of medication most likely to be used in this treatment for asthma management
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ragwitek) Reference Number: CP.PMN.83 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial, Medicaid See Important Reminder at the end of this policy for important
More informationLatest advances in the management of childhood allergic rhinitis
Latest advances in the management of childhood allergic rhinitis Jason Y K Chan Assistant Professor Department of Otorhinolaryngology, Head & Neck Surgery The Chinese University of Hong Kong Disclosures
More informationPRINCIPAL MEDICATION OPTIONS FOR RHINITIS
SEE INDICATED SUMMARY STATEMENT (SS#) DISCUSSION FOR SUPPORTING DATA ALLERGIC RHINITIS (AR): SEASONAL (SAR) AND PERENNIAL (PAR) MONOTHERAPY ORAL Antihistamines, oral (H1 receptor antagonists) (SS# 61-64)
More informationARIA. At-A-Glance Pocket Reference 2007
ARIA_Glance_2007_8pg:ARIA_Glance_English 9/14/07 3:10 PM Page 1 ARIA At-A-Glance Pocket Reference 2007 1 st Edition NEW ARIA UPDATE BASED ON THE ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA WORKSHOP REPORT
More informationNext page. Name MRN DOB Date. Telephone H W M. Pharmacy
University of Texas Medical School at Houston Department of Otorhinolaryngology- Head & Neck Surgery Texas Sinus Institute www.ut-ent.org New Patient Questionnaire Rev. 2014-07-19 FINAL REV Page 1 of 7
More informationGeneric (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Nausea LAST REVIEW 9/11/2018 THERAPEUTIC CLASS Gastrointestinal Disorders REVIEW HISTORY 12/16, 11/15, 11/07 LOB AFFECTED
More informationAllergy and inflammation
and inflammation 1 Allergic population hyper-producers of IgE consistently increasing western societies: ~20% of general population 2 Allergic population 3 Allergic triggers 4 Allergic triggers abnormal
More informationESTABLISHED PATIENT INFORMATION
Leaders in outcomes oriented, evidence based, compassionate, cost effective care ESTABLISHED PATIENT INFORMATION Hello, We are delighted that you have scheduled an appointment with Pulmonary Medicine,
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky (Oralair) Reference Number: CP.PMN.85 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid
More information31 - Respiratory System
31 - Respiratory System Asthma 1. Asthma has two components. Name the two components. 2. What are the common triggers of asthma? (LP p319) (e.g., pets) Upper respiratory infections ( ) 3. Describe a normal
More informationAllergic Rhinitis 6/10/2016. Clinical and Economic Impact. Clinical and Economic Impact. Symptoms. Genetic/Environmental factors
I have no disclosures to make other than I too suffer from allergic rhinitis Allergic Rhinitis Betsy Close, MD Assistant Professor UT College of Medicine, Department of Family Medicine Clinical and Economic
More informationAbortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Grastek) Reference Number: CP.PMN.84 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationAllergic Rhinitis: When to Refer to an Allergist
Allergic Rhinitis: When to Refer to an Allergist Kirsten Kloepfer, MD, MS Assistant Professor of Pediatrics Section of Pulmonary, Allergy and Sleep Medicine Disclosures NIH K23 American Academy of Allergy,
More informationPharmacotherapy for Allergic Rhinitis
Pharmacotherapy for Allergic Rhinitis William Reisacher, MD FACS FAAOA Assistant Professor Weill Cornell Medical College The Impact of Allergic Rhinitis Allergic rhinitis affects approximately 50 million
More informationOHIO MEDICAID PHARMACY COVERAGE
OHIO MEDICAID PHARMACY COVERAGE This information is intended for use by providers to help select the most appropriate cost-effective medication and formulation for their patients. Prescribers should utilize
More informationMiddleton Chapter 42b (pages ): Allergic and Nonallergic Rhinitis Prepared by: Tammy Peng, MD
FIT Board Review Corner November 2017 Welcome to the FIT Board Review Corner, prepared by Amar Dixit, MD, and Christin L. Deal, MD, senior and junior representatives of ACAAI's Fellows-In- Training (FITs)
More informationAETNA BETTER HEALTH OF TEXAS Provider Relations newsletter
AETNA BETTER HEALTH OF TEXAS Provider Relations newsletter Summer 2017 Table of contents Chief Medical Officer Comments and New Guideline Application...1 Chief Medical Officer Comments and Pharmacy Corner...2
More informationNasonex vs claritin The Borg System is 100 % Retrievable & Reusable Nasonex vs claritin
Nasonex vs claritin The Borg System is 100 % Nasonex vs claritin Claritin (loratadine) is a once-daily medicine for allergies that won't make you as sleepy as other medicines that work like it. Zyrtec
More informationSAN DIEGO ALLERGY ASTHMA & IMMUNOLOGY CONSULTANTS, INC
SAN DIEGO ALLERGY ASTHMA & IMMUNOLOGY CONSULTANTS, INC BERNARD A. FEIGENBAUM, M.D. FACP, FAAAAI 9850 GENESEE AVE, SUITE 355 CLINICAL ASSISTANT PROFESSOR OF MEDICINE & OTOLARYNGOLOGY, NYU LA JOLLA, CA 92037
More informationSecretary for Health and Family Services Selections for Preferred Products
Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based
More informationII. UF CLASS REVIEWS NASAL ALLERGY DRUGS
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code
More informationHayfever. Allergic reaction. Prognosis
Hayfever Hay fever is a type of allergic rhinitis caused by pollen or spores. Allergic rhinitis is a condition where an allergen (something that causes an allergic reaction) makes the inside of your nose
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationNew Patient Information
New Patient Information Thank you for choosing Central Indiana Allergy. In order to provide the most thorough evaluation of your problems, we ask for your assistance with the following items: Complete
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More informationInitial Allergy Questionnaire and History
Initial Allergy Questionnaire and History No Antihistamines for 72 hours prior to Testing appointments Your Appointment is on: DATE: TIME: WITH: Jean Carney, MD Kuo Casey Chang, MD Austin Sargent, MD,
More informationInitial Allergy Questionnaire and History
Initial Allergy Questionnaire and History Your Appointment is on: DATE: TIME: WITH: Michael Barrett, MD Office: No Antihistamines for 72 hours prior to Testing appointments Kuo Casey Chang, MD Erica Bocchi,
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More informationAllergies Formulary
Self-care should be encouraged as. Self Care The self care forum states: Empowering people with the confidence information to look after themselves when they can, visit the GP when they need to, gives
More informationMAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS
MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS The November 22, 2016 Mid-Year Financial Report referred to changes to drug coverage under the Saskatchewan Drug Plan. What
More informationANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component
ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate
More informationAllergic Rhinitis. Key Points:
University of Michigan Health System Guidelines for Clinical Care Allergic Rhinitis Allergic Rhinitis Guideline Team Richard Orlandi, MD Otolaryngology James Baker, MD Allergy Margie Andreae, MD Pediatrics
More informationAvailable Strengths Limits. 10 mg tablet -- $ mg tablet -- $ mg tablet -- $ mg tablet -- $72.41 Avoid use in members over
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Fibromyalgia P&T DATE: 5/9/2017 CLASS: Pain Management REVIEW HISTORY 9/15, 5/14, 11/12, 9/12, LOB: Medi-Cal (MONTH/YEAR)
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
RAGWITEK (Short Ragweed Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline
More informationAllergies Formulary. Self Care
How does the guidance apply to this formulary? For full information see: NHSE Guidance to CCGs A quick reference guide for professionals is also available which contains hyperlinks to the conditions for
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationMtM essentials for allergic rhinitis management
CREDIT: 2.0 Continuing Education EARN CE CREDIT FOR THIS ACTIVITY AT WWW.DRUGTOPICS.COM AN ONGOING CE PROGRAM OF THE UNIVERSITY OF CONNECTICUT SCHOOL OF PHARMACY AND DRUG TOPICS educational objectives
More informationDrug Effectiveness Review Project Literature Scan Summary. Month/Year of Review: January 2015 Date of Last Review: January 2013
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503 947 1119 Copyright 2012 Oregon State University. All Rights
More informationAdvanced Pharmacology Respiratory Pharmacology
Advanced Pharmacology Respiratory Pharmacology Thomas W. Barkley, Jr., PhD, ACNP BC, FAANP President, Barkley & Associates www.npcourses.com and Professor of Nursing Director of Nurse Practitioner Programs
More informationThe Safety of Asthma and Allergy Medications in Pregnancy: New Horizons
The Safety of Asthma and Allergy Medications in Pregnancy: New Horizons Jennifer Namazy, MD Division of Allergy Scripps Clinic, San Diego Michael Schatz, MD, MS Department of Allergy Kaiser Permanente,
More informationNew Patient Information
Rory L. Herron, ANP-BC New Patient Information Arrival Time: Appointment Time: Date: Thank you for choosing Central Indiana Allergy. In order to provide the most thorough evaluation of your problems, we
More informationGeneric Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)
More informationAllergic rhinitis is a very common condition
...CONTINUING PHARMACY EDUCATION... Drug Therapy of Allergic Rhinitis Timothy Self, PharmD; and Carol C. Chafin, PharmD AUDIENCE This activity is designed for pharmacists, pharmacy directors, managed care
More informationPharmacotherapy for Allergic Rhinitis
Disclosures: Pharmacotherapy for Allergic Rhinitis None John H. Krouse, MD, PhD, MBA Professor and Chairman Department of Otolaryngology-HNS Temple University School of Medicine Learning Objectives Describe
More informationTreatment of Allergic Rhinitis
Treatment of Allergic Rhinitis DENISE K.C. SUR, MD, and MONICA L. PLESA, MD, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California Allergic rhinitis is a common
More informationFormat. Allergic Rhinitis Optimising Mananagement. Degree of Quality of life Restriction in the Allergic Patient. The allergy epidemic:
Format Allergic Rhinitis Optimising Mananagement Dr Dominic Mallon FRACP FRCPA Clinical Immunologist and Allergist Fiona Stanley Hospital Impact of allergic rhinitis Diagnosis and management of allergic
More informationAllergic rhinitis (AR) is a highly prevalent disease, affecting
Cost Efficiency of Intranasal Corticosteroid Prescribing Patterns in the Management of Allergic Rhinitis DEBI REISSMAN, PharmD; TOM PRICE, BA; and CHRISTOPHER W. LEIBMAN, PharmD, MS ABSTRACT BACKGROUND:
More informationOphthalmic Antihistamine Step Therapy Program Summary
Ophthalmic Antihistamine Step Therapy Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-8 Drug FDA Indication(s) Administration and Dosing Bepreve Treatment of itching associated Instill one drop into
More informationCase Study. Allergic Rhinitis 5/18/2015
John A. Fling, M.D. Professor Allergy/Immunology University of North Texas Health Science Center, Fort Worth, Texas Case Study 38 year old male with a history of nasal congestion, clear nasal discharge
More informationALLERGIC RHINOSINUSITIS. Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences
ALLERGIC RHINOSINUSITIS Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences OVERVIEW Pathophysiology Goals of therapy Approaches to therapy Antihistaminics Corticosteroids
More informationcentral oregon EAR NOSE THROAT
Northwest Sinus Center Director: Ryan P. Gallivan, MD central oregon EAR NOSE THROAT New Patient Questionnaire Name MRN DOB Date Telephone H W M Pharmacy Name Telephone How did you hear about us? q Sent
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines
More informationALLERGY & ASTHMA ASSOCIATES PLEASE ARRIVE 15 MINUTES BEFORE YOUR APPOINTMENT TO PROCESS THE PAPERWORK - BRING ALL INSURANCE CARDS
ALLERGY & ASTHMA ASSOCIATES Harold Kreithen, M.D. Neil Feldman, D.O. Candace Kubek, C.R.N.P. This is to confirm your appointment on: Location: PLEASE ARRIVE 15 MINUTES BEFORE YOUR APPOINTMENT TO PROCESS
More informationRecommended Exclusion of Selected Discretionary Drugs
7100 N High Street Office Suite 305 Worthington, Ohio 43085 pharmaceuticalhorizons.com p 614.781.6500 f 614.781.6503 FROM: RE: Allan Zaenger R.Ph., MS Pharmaceutical Horizons, Inc. Recommended Exclusion
More informationDrugs Used to Treat Chronic Obstructive Pulmonary Disease (COPD)
Drugs Used to Treat Chronic Obstructive Pulmonary Disease (COPD) COPD COPD is a chronic, irreversible obstruction of airflow that is usually progressive. Symptoms include cough, excess mucus production,
More informationObjec9ves. Drug Classes with Indications to Treat AR. Allergic Rhinitis. Allergic Rhinitis. Action Statements
Sneezes, Wheezes, and espiratory Diseases: An update on Asthma, Allergic hini5s, and COPD Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates Objec9ves Evalua9on of the latest allergic
More informationXOLAIR (omalizumab) Prior Authorization
MP9309 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below May only be prescribed by Allergy, Pulmonary, Immunology or Dermatology specialists
More informationHealth New England (HNE) is making some changes to your Plan, most of which become effective July 1, 2015.
April 17, 2015 FULLY FUNDED PLANS ONLY RE: Semi-Annual Notice of Changes Dear HNE Member: Health New England (HNE) is making some changes to your Plan, most of which become effective July 1, 2015. I have
More informationEnvironmental Management of Asthma: Asthma Triggers
Environmental Management of Asthma: Asthma Triggers Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, RN, FNP-C, AE-C Asthma Network of West Michigan June 2015
More informationOpinion 5 February 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 5 February 2014 DYMISTA 137 µg/50 µg, nasal spray suspension Bottle with 23 g suspension of 25 ml or around 120 doses
More informationHigh ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal
More informationEnvironmental Management of Asthma 2017: Asthma Triggers
Environmental Management of Asthma 2017: Asthma Triggers Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, RN, FNP-C, AE-C Director, Commercial Care Management
More informationAvailable Strengths. Cost per Rx 325 mg tablet - $ mg tablet - $ mg ER tablet - $ mg capsule - $ mg chewable tablet
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Non-Opioids LAST REVIEW 5/9/2017 THERAPEUTIC CLASS Pain REVIEW HISTORY 2/16, 5/15 LOB AFFECTED Medi-Cal (MONTH/YEAR) This
More information**No food or beverages are allowed in the exam room**
ALLERGY & ASTHMA ASSOCIATES Neil Feldman, D.O. Rebecca Aul, C.R.N.P. This is to confirm your appointment on: Location: PLEASE ARRIVE 15 MINUTES BEFORE YOUR APPOINTMENT TO PROCESS THE PAPERWORK - BRING
More informationManaging allergic rhinitis
This lesson is supported by an educational grant from Managing allergic rhinitis Introduction Approximately 58 million Americans suffer from allergic rhinitis 1, making it the United State s sixth most-common
More information4240 Blue Ridge Blvd., Suite 1000 Kansas City, MO (816) Patient Instruction
www.silversteineyecenters.com 4240 Blue Ridge Blvd., Suite 1000 Kansas City, MO 64133 (816) 358.3600 Patient Instruction CONSENT FORM FOR ALLERGY SKIN TESTING Skin Test: Skin tests are methods of testing
More informationScottish Medicines Consortium
Scottish Medicines Consortium fluticasone furoate, 27.5 micrograms /actuation nasal (Avamys ) No. (544/09) GlaxoSmithKline 06 March 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationSeasonal Allergic Rhinoconjunctivitis
Seasonal Allergic Rhinoconjunctivitis Allergic rhinoconjunctivitis is a common condition. Most patients can achieve good symptom control through allergen avoidance and pharmacotherapy with non-sedating
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Immunotherapy Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Immunotherapy Agents Prime Therapeutics will review Prior Authorization
More information